10 completed, 2 terminated, 1 unknown. 13 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 10, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow brivanib: new trials by email Literature Review of brivanib trials Research Report on brivanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients MGD013 monotherapy, MGD013 in combination with Brivanib Alaninate - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Zai Lab (Shanghai) Co., Ltd. | 89 | 2020-04-20 | 2024-07-23 |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer niraparib, Brivanib - Ovarian Cancer | Phase 1 | Unknown | Hunan Cancer Hospital | 24 | 2019-01-14 | 2019-03-29 |
| Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) Brivanib - Hepatocellular Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 17 | 2012-03-01 | 2014-07-08 |
| Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) 5-FU, Leucovorin, Irinotecan - Gastro-Intestinal Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 49 | 2010-02-01 | 2014-09-16 |
| Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers Capecitabine, Doxorubicin, Ixabepilone - Advanced Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 111 | 2009-03-01 | 2015-07-07 |
| Phase I/II Combination With Irinotecan- Erbitux Cetuximab, Irinotecan, Brivanib - Metastatic Colorectal Cancer (MCRC) | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 38 | 2008-05-01 | 2015-11-04 |
| A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Brivanib - Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 13 | 2007-10-01 | 2011-01-25 |
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Brivanib - Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 4 | 2007-09-01 | 2009-01-22 |
| A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction Brivanib - Carcinoma, Hepatocellular | Phase 1 | Completed | Bristol-Myers Squibb | 24 | 2007-07-01 | 2011-05-04 |
| Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies BMS-582664 - Gastrointestinal Neoplasms | Phase 1 | Terminated | Bristol-Myers Squibb | 50 | 2006-04-01 | 2010-03-02 |
| BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies Brivanib + Cetuximab - Colorectal Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 62 | 2006-01-01 | 2011-01-25 |
| MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Brivanib, Brivanab - Tumors, Neoplasm Metastasis | Phase 1 | Completed | Bristol-Myers Squibb | 68 | 2004-09-01 | 2008-11-04 |
| A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) Brivanib - Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 29 | 2000-05-01 | 2013-06-21 |
Neoplasms (3) · Carcinoma, Hepatocellular (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Gastrointestinal Neoplasms (1) · Liver Neoplasms (1) · Ovarian Neoplasms (1) · Pyloric Stenosis, Hypertrophic (1)
Bristol-Myers Squibb (11) · Hunan Cancer Hospital (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (9) · Canada (4) · China (3) · Italy (2) · Spain (2) · Argentina (1) · Denmark (1) · France (1) · Japan (1) · Netherlands (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
2009 (1)